Erasca, Inc. Financing Cash Flow
Erasca, Inc. (ERAS) reported Financing Cash Flow of $247.73 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-11
- Erasca, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $3.06M, a 585.46% increase year-over-year.
- Erasca, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $244.66M, a 741306.06% increase year-over-year.
- Erasca, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $575.00K, a 28.21% decline year-over-year.
- Erasca, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $41.00K, a 99.81% decline year-over-year.
- Erasca, Inc. net cash provided by (used in) financing activities for fiscal 2025 was $1.10M, a 99.54% decline from fiscal 2024.
- Erasca, Inc. net cash provided by (used in) financing activities for fiscal 2024 was $240.70M, a 18486.64% increase from fiscal 2023.
- Erasca, Inc. net cash provided by (used in) financing activities for fiscal 2023 was $1.29M, a 98.68% decline from fiscal 2022.
- Erasca, Inc. net cash provided by (used in) financing activities for fiscal 2022 was $98.08M, a 77.68% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $247.73M 10-Q · filed 2026-08-11 | $248.30M derived: sum of 3 quarters · filed 2026-08-11 | $248.34M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $244.66M 10-Q · filed 2026-05-11 | $245.24M derived: sum of 2 quarters · filed 2026-05-11 | $245.28M derived: sum of 3 quarters · filed 2026-05-11 | $245.73M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $575.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $616.00K derived: sum of 2 quarters · filed 2026-03-12 | $1.06M derived: sum of 3 quarters · filed 2026-08-11 | $1.10M 10-K · filed 2026-03-12 |
| 2025-09-30 | $41.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $488.00K derived: sum of 2 quarters · filed 2026-08-11 | $521.00K 10-Q · filed 2025-11-12 | $1.32M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $447.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $480.00K 10-Q · filed 2026-08-11 | $1.28M derived: sum of 3 quarters · filed 2026-08-11 | $22.38M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $33.00K 10-Q · filed 2026-05-11 | $834.00K derived: sum of 2 quarters · filed 2026-05-11 | $21.93M derived: sum of 3 quarters · filed 2026-05-11 | $233.80M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $801.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $21.90M derived: sum of 2 quarters · filed 2026-03-12 | $233.77M derived: sum of 3 quarters · filed 2026-03-12 | $240.70M 10-K · filed 2026-03-12 |
| 2024-09-30 | $21.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $232.97M derived: sum of 2 quarters · filed 2025-11-12 | $239.90M 10-Q · filed 2025-11-12 | $240.35M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $211.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $218.80M 10-Q · filed 2025-08-12 | $219.25M derived: sum of 3 quarters · filed 2025-08-12 | $219.26M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $6.93M 10-Q · filed 2025-05-13 | $7.39M derived: sum of 2 quarters · filed 2025-05-13 | $7.39M derived: sum of 3 quarters · filed 2025-05-13 | $8.04M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $456.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $463.00K derived: sum of 2 quarters · filed 2025-03-20 | $1.11M derived: sum of 3 quarters · filed 2025-03-20 | $1.29M 10-K · filed 2025-03-20 |
| 2023-09-30 | $7.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $656.00K derived: sum of 2 quarters · filed 2024-11-12 | $839.00K 10-Q · filed 2024-11-12 | $97.03M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $649.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $832.00K 10-Q · filed 2024-08-12 | $97.03M derived: sum of 3 quarters · filed 2024-08-12 | $97.45M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $183.00K 10-Q · filed 2024-05-08 | $96.38M derived: sum of 2 quarters · filed 2024-05-08 | $96.81M derived: sum of 3 quarters · filed 2024-05-08 | $97.80M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | $96.20M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | $96.62M derived: sum of 2 quarters · filed 2024-03-27 | $97.61M derived: sum of 3 quarters · filed 2024-03-27 | $98.08M 10-K · filed 2024-03-27 |
| 2022-09-30 | $427.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $1.42M derived: sum of 2 quarters · filed 2023-11-09 | $1.88M 10-Q · filed 2023-11-09 | $2.99M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $992.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $1.45M 10-Q · filed 2023-08-10 | $2.56M derived: sum of 3 quarters · filed 2023-08-10 | $320.13M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $460.00K 10-Q · filed 2023-05-15 | $1.57M derived: sum of 2 quarters · filed 2023-05-15 | $319.14M derived: sum of 3 quarters · filed 2023-05-15 | $319.32M derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | $1.11M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $318.68M derived: sum of 2 quarters · filed 2023-03-23 | $318.86M derived: sum of 3 quarters · filed 2023-03-23 | $439.40M 10-K · filed 2023-03-23 |
| 2021-09-30 | $317.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $317.75M derived: sum of 2 quarters · filed 2022-11-09 | $438.29M 10-Q · filed 2022-11-09 | $438.18M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $180.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $120.72M 10-Q · filed 2022-08-11 | $120.61M derived: sum of 3 quarters · filed 2022-08-11 | $135.22M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $120.54M 10-Q · filed 2022-05-12 | $120.43M derived: sum of 2 quarters · filed 2022-05-12 | $135.04M derived: sum of 3 quarters · filed 2022-05-12 | |
| 2020-12-31 | -$111.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-24 | $14.50M derived: sum of 2 quarters · filed 2022-03-24 | $139.99M 10-K · filed 2022-03-24 | |
| 2020-09-30 | $14.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $140.10M 10-Q · filed 2021-11-10 | ||
| 2020-06-30 | $125.49M 10-Q · filed 2021-08-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |